- Home
- ALT vs TERN Comparison
ALT vs TERN Comparison
Compare ALT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- TERN
- Stock Information
- Founded
- ALT 1997
- TERN 2017
- Country
- ALT United States
- TERN United States
- Employees
- ALT N/A
- TERN 59
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- TERN Health Care
- Exchange
- ALT Nasdaq
- TERN Nasdaq
- Market Cap
- ALT 397.4M
- TERN 349.4M
- IPO Year
- ALT N/A
- TERN 2021
- Fundamental
- Price
- ALT $4.19
- TERN $4.90
- Analyst Decision
- ALT Strong Buy
- TERN Buy
- Analyst Count
- ALT 6
- TERN 5
- Target Price
- ALT $18.20
- TERN $15.63
- AVG Volume (30 Days)
- ALT 11.7M
- TERN 898.2K
- Earning Date
- ALT 08-07-2025
- TERN 08-04-2025
- Dividend Yield
- ALT N/A
- TERN N/A
- EPS Growth
- ALT N/A
- TERN N/A
- EPS
- ALT N/A
- TERN N/A
- Revenue
- ALT $20,000.00
- TERN N/A
- Revenue This Year
- ALT N/A
- TERN N/A
- Revenue Next Year
- ALT $1,557,547.90
- TERN N/A
- P/E Ratio
- ALT N/A
- TERN N/A
- Revenue Growth
- ALT N/A
- TERN N/A
- 52 Week Low
- ALT $2.90
- TERN $1.87
- 52 Week High
- ALT $11.16
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ALT 39.67
- TERN 68.87
- Support Level
- ALT $4.33
- TERN $3.95
- Resistance Level
- ALT $4.79
- TERN $4.97
- Average True Range (ATR)
- ALT 0.52
- TERN 0.34
- MACD
- ALT -0.16
- TERN 0.08
- Stochastic Oscillator
- ALT 26.92
- TERN 91.55
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.